Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 277, Issue 6 40-6, 1999, Pages

  Ahrén, Bo ^a,c   Pacini, Giovanni ^b  

^a LUND UNIVERSITY   (Sweden)

^b Inst Syst Sci Biomed Eng   (Italy)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Glucagon like peptide 1; Glucose disposal; Mouse

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

EID: 0033381349     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1999.277.6.e996     Document Type: Article

References (58)

1. Ader, M., G. Pacini, Y. J. Yang, and R. N. Bergman. Importance of glucose per se to intravenous glucose tolerance: comparison of the minimal-model prediction with direct measurements. Diabetes 34: 1092-1103, 1985.
2. Ahrén, B. Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. Endocrinology 3: 367-369, 1995.
3. Ahrén, B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 20: 642-651, 1998.
4. Ahrén, B. Insulinotropic action of truncated glucagon-like peptide-1 in mice. Acta Physiol. Scand. 153: 205-206, 1995.
5. Ahrén, B., and S. Karlsson. Role of islet neuropeptides in the regulation of insulin secretion. In: Insulin Secretion and Pancreatic B-Cell Research, edited by P. R. Flatt and S. Lenzen. London: Smith-Gordon, 1994, p. 313-318.
6. Ahrén, B., H. Larsson, and J. J. Holst. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82: 473-478, 1997.
7. Bergman, R. N. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38: 1512-1527, 1989.
8. Bergman, R. N., L. S. Phillips, and C. Cobelli. Physiologic evaluation of factors controlling glucose tolerance in man. J. Clin. Invest. 68: 1456-1467, 1981.
9. Best, J. D., S. E. Kahn, M. Ader, R. M. Watanabe, T. C. Ni, and R. N. Bergman. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19: 1018-1030, 1996.
10. D'Alessio, D. A., S. E. Kahn, C. R. Leusner, and J. W. Ensinck. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin. Invest. 93: 2263-2266, 1994.
11. D'Alessio, D. A., R. Vogel, R. Prigeon, E. Laschansky, D. Koerker, J. Eng, and J. W. Ensinck. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest. 97: 133-138, 1996.
12. Eng, J., W. A. Kleinman, L. Singh, G. Singh, and J. P. Raufman. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J. Biol. Chem. 267: 7402-7405, 1992.
13. Filipsson, K., G. Pacini, A. J. W. Scheurink, and B. Ahrén. PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. Am. J. Physiol. 274 (Endocrinol. Metab. 37): E834-E842, 1998.
14. Finegood, D. T. Application of the minimal model of glucose kinetics. In: The Minimal Model Approach and Determinants of Glucose Tolerance, edited by R. N. Bergman and J. C. Lovejoy. Baton Rouge, LA: Louisiana State Univ. Press, 1997, p. 51-122.
15. (7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action. Diabetes Res. Clin. Pract. 16: 185-191, 1991.
16. 7-36 amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6: 208-215, 1991.
17. Fürnsinn, C., K. Ebner, and W. Waldhäusl. Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38: 864-867, 1995.
18. Göke, R., H. C. Fehmann, T. Linn, H. Schmidt, M. Krause, J. Eng, and B. Göke. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin secreting beta-cells. J. Biol. Chem. 268: 19650-19656, 1993.
19. Göke, R., B. Wagner, H. C. Fehmann, and B. Göke. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res. Exp. Med. (Berl.) 197: 97-103, 1993.
20. Gromada, J., J. J. Holst, and P. Rorsman. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch. 435: 583-594, 1998.
21. Gutniak, M. K., H. Larsson, S. J. Heiber, O. T. Juneskans, J. J. Holst, and B. Ahrén. Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 19: 843-848, 1996.
22. Gutniak, M. K., H. Larsson, S. W. Sanders, O. Juneskans, J. J. Holst, and B. Ahrén. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20: 1874-1879, 1997.
23. Gutniak, M., C. Ørskov, J. Holst, B. Ahrén, and S. Efendic. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326: 1316-1322, 1992.
24. Habener, J. F. The incretin notion and its relevance to diabetes. Endocrinol. Metab. Clin. North Am. 22: 775-794, 1994.
25. Hansen, B. F., P. Jensen, E. Nepper-Christensen, and B. Skjølstrup. Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol. 35: 101-1093, 1998.
26. Hargrove, D. M., N. A. Nardone, L. M. Persson, J. C. Parker, and R. W. Stevenson. Glucose-dependent action of glucagon-like peptide-1(7-37) in vivo during short-or long-term administration. Metabolism 44: 1231-1237, 1995.
27. Holst, J. J. Glucagonlike peptide 1. Curr. Opin. Endocrinol. Diabetes 4: 256-261, 1997.
28. Holst, J. J., C. Ørskov, O. Vagn Nielsen, and T. W. Schwartz. Truncated glucagon-like peptide 1, an insulin releasing hormone from the distal gut. FEBS Lett. 211: 169-174, 1987.
29. Holz, G. G., W. M. Kuhtreiber, and J. F. Habener. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361: 362-365, 1993.
30. Hvidberg, A., M. Toft-Nielsen, J. Hilsted, C. Ørskov, and J. J. Holst. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 43: 104-108, 1994.
31. Juntti-Berggren, L., J. Pigon, F. Karpe, A. Hamsten, M. Gutniak, L. Vignati, and S. Efendic. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19: 1200-1206, 1996.
32. Karlsson, S., A. J. W. Scheurink, A. B. Steffens, and B. Ahrén. Involvement of capsaicin-sensory nerves in regulation of insulin secretion and glucose tolerance in conscious mice. Am. J. Physiol. 267 (Regulatory Integrative Comp. Physiol. 36): R1071-R1077, 1994.
33. Kolligs, F., H. C. Fehmann, R. Göke, and B. Göke. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19, 1995.
34. Kreymann, B., G. Williams, M. A. Ghatei, and S. R. Bloom. Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2: 1300-1304, 1987.
35. Larsson, H., J. J. Holst, and B. Ahrén. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol. Scand. 160: 413-422, 1997.
36. Lönnroth, P., J. I. Davies, I. Lönnroth, and U. Smith. The interaction between the adenylate cyclase system and insulin-stimulated glucose transport. Evidence for the importance of both cyclic AMP-dependent and -independent mechanisms. Biochem. J. 243: 798-795, 1987.
37. Mandarino, L., B. Baker, R. Rizza, J. Genest, and J. Gerich. Infusion of insulin impairs human adipocyte glucose metabolism in vitro without decreasing adipocyte insulin receptor binding. Diabetologia 27: 358-363, 1984.
38. Marangou, A. G., K. M. Weber, R. C. Boston, P. M. Aitken, J. C. Heggie, R. L. Kirsner, J. D. Best, and F. P. Alford. Metabolic concequences of prolonged hyperinsulinemia in humans. Evidence for induction of insulin insensitivity. Diabetes 35: 1383-1389, 1996.
39. Miki, H., M. Namba, T. Nishimura, I. Mineo, T. Matsumura, J. Miyagawa, H. Nakajima, M. Kuwajima, T. Hanafusa, and Y. Matsuzawa. Glucagon-like peptide-1 (7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochim. Biophys. Acta 1312: 132-136, 1996.
40. Mojsov, S., G. C. Weir, and J. F. Habener. Insulinotropin: glucagon-like peptide-1 (7-37) coencoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79: 616-619, 1987.
41. Nauck, M. A., J. J. Holst, B. Willms, and W. Schmiegel. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 105: 187-195, 1997.
42. Nauck, M. A., N. Kleine, C. Ørskov, J. J. Holst, B. Willms, and W. Creutzfeldt. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993.
43. Nauck, M. A., I. Weber, I. Bach, S. Richter, C. Ørskov, J. J. Holst, and W. Schmiegel. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet. Med. 15: 937-945, 1998.
44. Ørskov, C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711, 1992.
45. Ørskov, L., J. J. Holst, J. Møller, C. Ørskov, N. Møller, K. G. Alberti, and O. Schmitz. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232, 1996.
46. Pacini, G., G. Tonolo, M. Sambataro, M. Maioli, M. Ciccarese, E. Brocco, A. Avogaro, and R. Nosadini. Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am. J. Physiol. 274 (Endocrinol. Metab. 37): E592-E599, 1998.
47. Perea, A., C. Vinambres, F. Clemente, M. L. Villanueva-Penacarrillo, and I. Valverde. GLP-1 (7-36) amide: effects on glucose transport and metabolism in rat adipose tissue. Horm. Metab. Res. 29: 417-421, 1997.
48. Ritzel, R., C. Ørskov, J. J. Holst, and M. A. Nauck. Pharmacokinetic, insulinotropic and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38: 720-725, 1995.
49. Rizza, R. A., L. J. Mandarino, J. Genest, B. A. Baker, and J. E. Gerich. Production of insulin resistance by hyperinsulin-aemia in man. Diabetologia 28: 70-75, 1985.
50. Saad, M. F., G. M. Steil, W. W. Kades, M. F. Ayad, W. A. Elsewafy, R. Boydadjian, S. D. Jinagouda, and R. N. Bergman. Differences between the tolbutamide-boosted and the insulin-modified minimal model protocols. Diabetes 46: 1167-1171, 1997.
51. Saad, M. F., G. M. Steil, M. Riad Gabriel, A. Jhan, A. Sharma, R. Boyadjian, S. D. Jinagouda, and R. N. Bergman. Method of insulin administration has no effect on insulin sensitivity estimates from the insulin-modified minimal model protocol. Diabetes 46: 2044-2048, 1997.
52. Schirra, J., K. Sturm, P. Leicht, R. Arnold, B. Göke, and M. Katschinsky. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J. Clin. Invest. 101: 1421-1430, 1998.
53. Thorens, B. Expression cloning of the pancreatic beta cell receptor of the gluco-incretin hormone glucagon-like peptide I. Proc. Natl. Acad. Sci. USA 89: 8641-8645, 1992.
54. Valverde, I., M. Morales, F. Clemente, M. I. Lopez Delgado, E. Delgado, A. Perea, and M. L. Villanueva-Penacarrillo. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 349: 313-316, 1994.
55. Van Dijk, G., S. Lindskog, J. J. Holst, A. B. Steffens, and B. Ahrén. Effects of glucagon-like peptide 1 on glucose turnover in rats. Am. J. Physiol. 270 (Endocrinol. Metab. 33): E1015-E1021, 1996.
56. Villanueva-Penacarrillo, M. L., A. I. Alcantara, F. Clemente, E. Delgado, and I. Valverde. Potent glycogenic effect of GLP-1 (7-36)amide in rat skeletal muscle. Diabetologia 37: 1163-1166, 1994.
57. Weir, G. C., S. Mojsov, G. K. Hendrick, and J. F. Habener. Glucagon-like peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-352, 1989.
58. Willms, B., J. Werner, J. J. Holst, C. Ørskov, W. Creutzfeldt, and M. A. Nauck. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81: 327-332, 1996.